Follicular Thyroid Cancer Incidence Patterns in the United States, 1980–2009

Aschebrook‐Kilfoy, Briseis; Grogan, Raymon H.; Ward, Mary H.; Kaplan, Edwin L.; Devesa, Susan S.

doi:10.1089/thy.2012.0356

Cited by 117 publications

(81 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are no uniform epidemiological data with respect to the incidence of FTC. A current study showed an increase in the USA of 30 % between 1980 and 2009 for occurrences of FTC [11]. In all age groups, FTC appeared more frequently among women.…”

mentioning

confidence: 44%

Differential Diagnostic Ultrasound Criteria of Papillary and Follicular Carcinomas: A Multivariate Analysis

Cordes

Kondrat

Uder

et al. 2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 44%

Differential Diagnostic Ultrasound Criteria of Papillary and Follicular Carcinomas: A Multivariate Analysis

Cordes

Kondrat

Uder

et al. 2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

show abstract

“…Thyroid carcinoma is the most common malignancy of the endocrine system showing increasing incidences over the years (1)(2)(3), with age-standardized rates (ASR) of about 6/100,000 in the developed countries. Particularly elevated ASRs were observed in Lithuania (ASR ¼ 15.5/100,000), Italy (ASR ¼ 13.5/100,000), Austria (ASR ¼ 12.4/100,000), and in the United States (ASR ¼ 9.9/100,000; refs.…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive Meta-analysis of Case–Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma

Figlioli

Elisei

Romei

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Linkage analyses and association studies suggested that inherited genetic variations play a role in the development of differentiated thyroid carcinoma (DTC).Methods: We combined the results from a genome-wide association study (GWAS) performed by our group and from published studies on DTC. With a first approach, we evaluated whether a SNP published as associated with the risk of DTC could replicate in our GWAS (using FDR as adjustment for multiple comparisons). With the second approach, meta-analyses were performed between literature and GWAS when both sources suggested an association, increasing the statistical power of the analysis.Results: rs1799814 (CYP1A1), rs1121980 (FTO), and 3 SNPs within 9q22 (rs965513, rs7048394, and rs894673)

show abstract

“…Concurrently, equal trends in the increase in incidence rate have been identified all over the world (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). The age-standardized incidence rate of thyroid cancer has increased from 1.1/100,000 to 6.1/100,000 for males, and from 3.3/100,000 to 22.2/100,000 for females, from 1970 to 1972 in the USA (1,15). A previous study indicated that the thyroid cancer incidence rate in Canada was the fastest increasing rate in the world, t trends in the incidence rate of thyroid cancer have demonstrated a 6.8% increase for males and 6.9% increase for females per annum between 1998 and 2007 (16)(17)(18).…”

Section: Introductionmentioning

confidence: 95%

Therapeutic effects of adenovirus‑mediated CD and NIS expression combined with Na131I/5‑FC on human thyroid cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Thyroid cancer is the most common type of malignant endocrine tumor diagnosed. Previous studies have indicated that gene therapy is the most promising and effective therapeutic method for thyroid cancer. Therefore, in the present study, Na 131 I/5-fluorocytosine (5-FC) treatment was combined with cytosine deaminase (CD, encoded by the CDA gene) and sodium iodide symporter (NIS, encoded by the SLC5A5 gene) to act together as a therapeutic tool for thyroid cancer. The present study explored the combined cytotoxic effects of adenovirus-mediated CD and NIS under the control of the progression elevated gene-3 (PEG-3) promoter (Ad-PEG-3-CD-NIS) with Na 131 I/5-FC against the human thyroid cancer TT cell line in vitro. The PEG-3 fragment was obtained by polymerase chain reaction (PCR) using rat genomic DNA as the template, and then Ad-PEG-3-CDA-SLC5A5 was constructed using XbaI. TT cells were transfected by recombinant adenovirus. The method of reverse transcription-quantitative PCR was performed to test the expression of CD and NIS at the level of transcription. The morphological change was assessed by fluorescence microscopy and investigated by western blot analysis. An MTT assay was used to determine the number of living cells inhibited by single or combination therapies on TT cells. The results indicated that the PEG-3 was successfully cloned, and was also positively regulated in 293 cells. CDA and SLC5A5 genes were highly expressed in TT cells. Na 131 I combined with 5-FC significantly decreased the human thyroid cancer cells. In conclusion, combination therapy of Ad-PEG3-CDA-SLC5A5 and Na 131 I/5-FC induces significantly more apoptotic characteristics than either single treatment with Ad-PEG-3-CDA-SLC5A5 or Na 131 I/5-FC, and low doses of Ad-PEG-3-CDA-SLC5A5 enhanced the cytotoxic effects.

show abstract

Follicular Thyroid Cancer Incidence Patterns in the United States, 1980–2009

Cited by 117 publications

References 21 publications

Differential Diagnostic Ultrasound Criteria of Papillary and Follicular Carcinomas: A Multivariate Analysis

Differential Diagnostic Ultrasound Criteria of Papillary and Follicular Carcinomas: A Multivariate Analysis

A Comprehensive Meta-analysis of Case–Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma

Therapeutic effects of adenovirus‑mediated CD and NIS expression combined with Na131I/5‑FC on human thyroid cancer

Contact Info

Product

Resources

About